Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Language
Publication year range
1.
Biomed Chromatogr ; 35(9): e5147, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33885176

ABSTRACT

Rivaroxaban is an anticoagulant (orally active direct Xa inhibitor) considered to reduce the risk of stroke and systemic embolism and treat deep vein thrombosis, pulmonary embolism, and other cardiovascular complications. Bioanalytical methods for rivaroxaban quantification in plasma are necessary for application in pharmacokinetic studies, as well as in drug therapeutic monitoring. In this work, we developed and validated a sensitive bioanalytical method using LC-MS/MS for rivaroxaban quantification in human plasma using an one-step liquid-liquid extraction. The linear concentration range was 1-600 ng/mL. The bioanalytical method was also applied to pharmacokinetic studies in healthy volunteers under fasting and fed conditions. The results demonstrated that the method is rapid, sensitive, and adequate for application in pharmacokinetic studies.


Subject(s)
Chromatography, Liquid/methods , Rivaroxaban/blood , Rivaroxaban/pharmacokinetics , Tandem Mass Spectrometry/methods , Adolescent , Adult , Humans , Limit of Detection , Linear Models , Liquid-Liquid Extraction , Middle Aged , Reproducibility of Results , Rivaroxaban/chemistry , Rivaroxaban/isolation & purification , Young Adult
2.
Braz J Med Biol Res ; 52(4): e8006, 2019 Apr 08.
Article in English | MEDLINE | ID: mdl-30970082

ABSTRACT

The aim of the study was to evaluate the diagnostic accuracy of thromboelastometry for assessing rivaroxaban concentrations. The accuracy of thromboelastometry was compared with the high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method, which is the gold standard for drug plasma monitoring (the reference standard). Forty-six clinically stable patients were treated with 10, 15, or 20 mg of rivaroxaban once daily (OD group) or 15 mg twice a day (BID group) (no particular indication for treatment). Patient samples were collected 2 h after the use of the medication (peak) and 2 h before the next dose (trough). The rivaroxaban plasma concentrations were determined via HPLC-MS/MS, and thromboelastometry was performed using a ROTEM® delta analyzer. There were significant prolongations in clotting time (CT) for the 10, 15, and 20 mg of rivaroxaban treatments in the OD groups. In the 15 mg BID group, the responses at the peak and trough times were similar. At the peak times, there was a positive correlation between the plasma concentration of rivaroxaban and CT (Spearman correlation rho=0.788, P<0.001) and clot formation time (rho=0.784, P<0.001), and a negative correlation for alpha angle (rho=-0.771, P<0.001), amplitude after 5 min (rho=-0.763, P<0.001), and amplitude after 10 min (rho=-0.680, P<0.001). The CT presented higher specificity and sensitivity using the cut-off determined by the receiver characteristics curve. ROTEM has potential as screening tool to measure possible bleeding risk associated with rivaroxaban plasma levels.


Subject(s)
Drug Monitoring/methods , Factor Xa Inhibitors/blood , Hemorrhage/prevention & control , Rivaroxaban/blood , Adult , Aged , Aged, 80 and over , Blood Coagulation Tests , Chromatography, High Pressure Liquid , Data Accuracy , Factor Xa Inhibitors/administration & dosage , Female , Humans , Male , Middle Aged , Rivaroxaban/administration & dosage , Tandem Mass Spectrometry , Thrombelastography
3.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;52(4): e8006, 2019. tab, graf
Article in English | LILACS | ID: biblio-1001515

ABSTRACT

The aim of the study was to evaluate the diagnostic accuracy of thromboelastometry for assessing rivaroxaban concentrations. The accuracy of thromboelastometry was compared with the high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method, which is the gold standard for drug plasma monitoring (the reference standard). Forty-six clinically stable patients were treated with 10, 15, or 20 mg of rivaroxaban once daily (OD group) or 15 mg twice a day (BID group) (no particular indication for treatment). Patient samples were collected 2 h after the use of the medication (peak) and 2 h before the next dose (trough). The rivaroxaban plasma concentrations were determined via HPLC-MS/MS, and thromboelastometry was performed using a ROTEM® delta analyzer. There were significant prolongations in clotting time (CT) for the 10, 15, and 20 mg of rivaroxaban treatments in the OD groups. In the 15 mg BID group, the responses at the peak and trough times were similar. At the peak times, there was a positive correlation between the plasma concentration of rivaroxaban and CT (Spearman correlation rho=0.788, P<0.001) and clot formation time (rho=0.784, P<0.001), and a negative correlation for alpha angle (rho=−0.771, P<0.001), amplitude after 5 min (rho=−0.763, P<0.001), and amplitude after 10 min (rho=−0.680, P<0.001). The CT presented higher specificity and sensitivity using the cut-off determined by the receiver characteristics curve. ROTEM has potential as screening tool to measure possible bleeding risk associated with rivaroxaban plasma levels.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Drug Monitoring/methods , Factor Xa Inhibitors/blood , Rivaroxaban/blood , Hemorrhage/prevention & control , Thrombelastography , Blood Coagulation Tests , Chromatography, High Pressure Liquid , Tandem Mass Spectrometry , Factor Xa Inhibitors/administration & dosage , Rivaroxaban/administration & dosage , Data Accuracy
SELECTION OF CITATIONS
SEARCH DETAIL